Hosted on MSN40m
GLP-1 Drug Shortage Is Over. Why Might These Drugs Soon Be Costlier and Harder to Access?
In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...
Eli Lilly Just Hit a Milestone That Disappointed. Here's Why You Should Still Buy the Stock.
Even a juggernaut like Eli Lilly ( LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat ...
AOL11h
Investors Like Certainty. Trump's Win Gave Them Some.
Why Novo Nordisk and Eli Lilly are giving totally different reads on the markets for GLP-1 drugs like Wegovy and Zepbound. To catch full episodes of all The Motley Fool's free podcasts, check out our ...
Hosted on MSN19h
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 Years
SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
BioWorld21h
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide ...